See more : Fuji Media Holdings, Inc. (FJTNF) Income Statement Analysis – Financial Results
Complete financial analysis of Sight Sciences, Inc. (SGHT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sight Sciences, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Aether Industries Limited (AETHER.BO) Income Statement Analysis – Financial Results
- Regis Corporation (RGS) Income Statement Analysis – Financial Results
- Baru Gold Corporation (BARUF) Income Statement Analysis – Financial Results
- Datatec Limited (DTTLY) Income Statement Analysis – Financial Results
- Sonagi, S.G.P.S., S.A. (SNG.LS) Income Statement Analysis – Financial Results
Sight Sciences, Inc. (SGHT)
About Sight Sciences, Inc.
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 81.06M | 71.33M | 48.96M | 27.64M | 23.35M | 7.53M |
| Cost of Revenue | 11.88M | 12.36M | 8.61M | 9.21M | 6.54M | 2.34M |
| Gross Profit | 69.18M | 58.97M | 40.35M | 18.43M | 16.80M | 5.19M |
| Gross Profit Ratio | 85.34% | 82.67% | 82.41% | 66.68% | 71.97% | 68.95% |
| Research & Development | 17.56M | 22.86M | 15.63M | 8.87M | 8.12M | 5.43M |
| General & Administrative | 106.79M | 117.47M | 74.09M | 40.95M | 30.92M | 13.06M |
| Selling & Marketing | 2.10M | 2.60M | 2.10M | 800.00K | 1.80M | 1.00M |
| SG&A | 108.89M | 120.07M | 76.19M | 41.75M | 32.72M | 14.06M |
| Other Expenses | 0.00 | 2.23M | -6.93M | -71.00K | -35.00K | 0.00 |
| Operating Expenses | 126.45M | 142.92M | 91.82M | 50.62M | 40.84M | 19.49M |
| Cost & Expenses | 138.33M | 155.29M | 100.43M | 59.83M | 47.39M | 21.83M |
| Interest Income | 0.00 | 4.47M | 4.37M | 30.00K | 174.00K | 1.00K |
| Interest Expense | 5.41M | 4.47M | 4.37M | 2.40M | 1.96M | 0.00 |
| Depreciation & Amortization | 614.00K | 1.25M | 1.20M | 1.12M | 432.00K | 63.00K |
| EBITDA | -49.42M | -80.48M | -57.21M | -31.68M | -23.47M | -14.23M |
| EBITDA Ratio | -60.96% | -114.58% | -119.30% | -114.60% | -101.10% | -189.02% |
| Operating Income | -57.27M | -83.95M | -51.48M | -32.19M | -24.04M | -14.30M |
| Operating Income Ratio | -70.66% | -117.70% | -105.15% | -116.45% | -102.96% | -189.87% |
| Total Other Income/Expenses | 1.84M | -2.24M | -11.29M | -2.44M | -1.82M | 1.00K |
| Income Before Tax | -55.44M | -86.20M | -62.77M | -34.63M | -25.86M | -14.30M |
| Income Before Tax Ratio | -68.39% | -120.84% | -128.22% | -125.30% | -110.76% | -189.85% |
| Income Tax Expense | 110.00K | 47.00K | 188.00K | 61.00K | 8.00K | -6.00K |
| Net Income | -55.55M | -86.24M | -62.96M | -34.69M | -25.87M | -14.29M |
| Net Income Ratio | -68.53% | -120.90% | -128.61% | -125.52% | -110.80% | -189.77% |
| EPS | -1.14 | -1.80 | -1.33 | -0.74 | -0.55 | -0.44 |
| EPS Diluted | -1.14 | -1.80 | -1.33 | -0.74 | -0.55 | -0.44 |
| Weighted Avg Shares Out | 48.63M | 47.85M | 47.50M | 46.77M | 46.77M | 32.20M |
| Weighted Avg Shares Out (Dil) | 48.63M | 47.85M | 47.50M | 46.77M | 46.77M | 32.20M |
Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology
Prospective, long-term trial results are consistent with the significant body of published clinical evidence demonstrating the durable safety and effectiveness of procedures enabled with the OMNI Surgical System technology
5 Risky Stocks to Buy Immediately, According to AI
This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here.
Sight Sciences, Inc. (SGHT) Q3 2023 Earnings Call Transcript
Sight Sciences, Inc. (NASDAQ:SGHT ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Founder and Chief Executive Officer Ali Bauerlein - Chief Financial Officer Matt...
Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023
MENLO PARK, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported...
Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023
MENLO PARK, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced...
Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023
The event will include a presentation from Brandon Ayres, MD, Wills Eye Hospital and Sight Sciences executive management team on the successful six month results of the SAHARA head-to head randomized controlled clinical trial comparing TearCare® to Restasis® for the...
Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting
Interventional eyelid procedures enabled by TearCare technology successfully delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through six months Interventional eyelid procedures enabled by TearCare technology successfully delivered clinically and statistically significant...
Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
Efficacy of the Three Most Commonly Used MIGS Technologies plus Cataract Surgery and Cataract Surgery Alone Were Evaluated and Compared in over 100,000 Glaucoma Patient Eyes Efficacy of the Three Most Commonly Used MIGS Technologies plus Cataract Surgery and Cataract...
Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3 - Sight Sciences (NASDAQ:SGHT), Scilex Holding (NASDAQ:SCLX)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Sight Sciences' stock tumbled 32% premarket after revenue warning
Sight Sciences Inc.'s stock SGHT, +6.03% tumbled 32% premarket Tuesday, after the eyecare technology company issued a revenue warning, saying it's seen fewer Surgical Glaucoma new accounts in the third quarter amid reimbursement uncertainty. The Menlo Park, Calif.
Source: https://incomestatements.info
Category: Stock Reports